Home › Trial NCT02443883
A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer
- Trial IDNCT02443883
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorEli Lilly and Company
- Enrollment164
- Start date2015-07-07
- ConditionsGastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.